What is Colivelin?
A hybrid peptide that joins activity-dependent neurotrophic factor (ADNF) to a potent humanin analog; studied in Alzheimer's and ALS models.
Colivelin in the library · · Human Trials · What are peptides?
0 registered trials · 0 indexed papers · 0 human / 11 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Colivelin is described as a fusion of a short ADNF segment with a modified humanin. Humanin has its own page.
Mechanism (as described)
- It activates STAT3 survival signaling in neurons (Chiba et al., 2009).
Evidence (as described)
- Animal and cell research only (Matsuoka et al., 2006). No human trials.
Status
Not approved.
More cited research
- Colivelin, a synthetic derivative of humanin, ameliorates endothelial injury and glycocalyx shedding after sepsis in mice (2022, animal)
- Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway (2019, animal)
- Colivelin Ameliorates Impairments in Cognitive Behaviors and Synaptic Plasticity in APP/PS1 Transgenic Mice (2017, animal)
- Protective Effects of Colivelin Against Alzheimer's Disease in a PDAPP Mouse Model (2016, animal)
Related compounds
FAQ
What is Colivelin?
A hybrid peptide that joins activity-dependent neurotrophic factor (ADNF) to a potent humanin analog; studied in Alzheimer's and ALS models.
How many registered human trials study Colivelin?
The PeptideWhiz trial index lists 0 registered trials for Colivelin.
How much published research exists on Colivelin?
By study type, PeptideWhiz counts 0 human and 11 animal studies on Colivelin.
Which conditions is Colivelin researched for?
No condition pages are linked to this compound yet.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).